• Allerton, C.M.N., Arcari, J.T., Aschenbrenner, L.M., Avery, M., Bechle, B.M., Behzadi, M.A., Boras, B., Buzon, L.M., Cardin, R.D., Catlin, N.R., Carlo, A.A., Coffman, K.J., Dantonio, A., Di, L., Eng, H., Farley, K.A., Ferre, R.A., Gernhardt, S.S., Gibson, S.A., Greasley, S.E., Greenfield, S.R., Hurst, B.L., Kalgutkar, A.S., Kimoto, E., Lanyon, L.F., Lovett, G.H., Lian, Y., Liu, W., Alsina, L.A.M., Noell, S., Obach, R.S., Owen, D.R., Patel, N.C., Rai, D.K., Reese, M.R., Rothan, H.A., Sakata, S., Sammons, M.F., Sathish, J.G., Sharma, R., Steppan, C.M., Tuttle, J.B., Verhoest, P.R., Wei, L., Yang, Q., Yurgelonis, I., Zhu, Y., 2024. A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19. J. Med. Chem. 67, 13550-13571.

  • Bai, J., Asakawa, T., Yuan, W., Lin, Y., Ju, H., Xu, D., Yang, M., Li, S., Li, G., Guo, D., Lu, H., Zhang, X., 2025. Efficacy and safety of SHEN26, a novel oral small molecular RdRp inhibitor for COVID-19 treatment: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial. Virol. J. 22, 16.

  • Cao, L., Li, Y., Yang, S., Li, G., Zhou, Q., Sun, J., Xu, T., Yang, Yang, Liao, R., Shi, Y., Yang, Yujian, Zhu, T., Huang, S., Ji, Y., Cong, F., Luo, Y., Zhu, Y., Luan, H., Zhang, H., Chen, J., Liu, X., Luo, R., Liu, L., Wang, P., Yu, Y., Xing, F., Ke, B., Zheng, H., Deng, X., Zhang, W., Lin, C., Shi, M., Li, C.-M., Zhang, Y., Zhang, L., Dai, J., Lu, H., Zhao, J., Zhang, X., Guo, D., 2022. The adenosine analog prodrug ATV006 is orally bioavailable and has preclinical efficacy against parental SARS-CoV-2 and variants. Sci. Transl. Med. 14, eabm7621.

  • Gidari, A., Sabbatini, S., Schiaroli, E., Bastianelli, S., Pierucci, S., Busti, C., Saraca, L.M., Capogrossi, L., Pasticci, M.B., Francisci, D., Gidari, A., Sabbatini, S., Schiaroli, E., Bastianelli, S., Pierucci, S., Busti, C., Saraca, L.M., Capogrossi, L., Pasticci, M.B., Francisci, D., 2023. Synergistic Activity of Remdesivir-Nirmatrelvir Combination on a SARS-CoV-2 In Vitro Model and a Case Report. Viruses 15, 1577.

  • Hirsch, C., Kreuzberger, N., Skoetz, N., Monsef, I., Kluge, S., Spinner, C.D., Malin, J.J., 2025. Efficacy and safety of antiviral therapies for the treatment of persistent COVID-19 in immunocompromised patients since the Omicron surge: a systematic review. J. Antimicrob. Chemother. 80, 633-644.

  • Mortezavi, M., Sloan, A., Singh, R.S.P., Chen, L.F., Kim, J.H., Shojaee, N., Toussi, S.S., Prybylski, J., Baniecki, M.L., Bergman, A., Banerjee, A., Allerton, C., Alami, N.N., 2024. Virologic Response and Safety of Ibuzatrelvir, A Novel SARS-CoV-2 Antiviral, in Adults With COVID-19. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 80, 673-680.

  • Soares, V.C., Moreira, I.B.G., Dias, S.S.G., 2025. SARS-CoV-2 Infection and Antiviral Strategies: Advances and Limitations. Viruses 17, 1064.

  • Xia, S., Lan, Q., Zhu, Y., Wang, C., Xu, W., Li, Y., Wang, L., Jiao, F., Zhou, J., Hua, C., Wang, Q., Cai, X., Wu, Y., Gao, J., Liu, H., Sun, G., Munch, J., Kirchhoff, F., Yuan, Z., Xie, Y., Sun, F., Jiang, S., Lu, L., 2021. Structural and functional basis for pan-CoV fusion inhibitors against SARS-CoV-2 and its variants with preclinical evaluation. Signal Transduct. Target. Ther. 6, 288.

  • Xia, S., Liu, M., Wang, C., Xu, W., Lan, Q., Feng, S., Qi, F., Bao, L., Du, L., Liu, S., Qin, C., Sun, F., Shi, Z., Zhu, Y., Jiang, S., Lu, L., 2020. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res. 30, 343-355.

  • Zhou, Q., Yang, S., Cao, L., Yang, Y., Xu, T., Chen, Q., Lu, H., Li, Y., Guo, D., Zhang, X., 2023. Preclinical characterization and anti-SARS-CoV-2 efficacy of ATV014: an oral cyclohexanecarboxylate prodrug of 1'-CN-4-aza-7,9-dideazaadenosine C-nucleoside. Signal Transduct. Target. Ther. 8, 27.